Pulmonary fibrosis in systemic sclerosis: Is treatment with cyclophosphamide more effective than placebo? Commentary

Nature Clinical Practice Rheumatology

Volumn 3, Issue 7, 2007, Pages 372-373

  Miniati, Irene ^a   Cerinic, Marco Matucci ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; PLACEBO; PREDNISOLONE;

CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEMATURIA; HUMAN; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SHORT SURVEY; SIDE EFFECT; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; TREND STUDY;

EID: 34447115935     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0507     Document Type: Short Survey

References (5)

1. White B et al. (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132: 947-954
2. Giacomelli R et al. (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29 731-736
3. Jadad AR (1998) Randomised controlled trials. London: BMJ Books
4. Tashkin DP et al. (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354: 2655-2666
5. Nadashkevic O et al. (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25: 205-212